|
|
NEW ON THE MARKET
|
|
Rifaximin (XIFAXAN) for the prevention of hepatic encephalopathy
|
|
|
TREATMENT RECOMMENDATION
|
|
Switching of levothyroxine preparations
|
|
|
a-t READERS' QUESTIONS AND COMMENTS
|
|
Mistletoe for cancer: What is the current state of scientific knowledge?
Rebates according to the Pharmaceutical Market Restructuring Act in Germany (AMNOG) in relation to comparative treatment and added benefit
Switching to generics in antiepileptic treatment
|
|
|
IN BRIEF
|
|
Sanofi - fines for disinformation campaign against clopidogrel generics
Physical therapy first option for knee osteoarthritis with meniscal tear
TEBONIN 120 mg BEI OHRGERÄUSCHEN [Ginkgo biloba for tinnitus]
FUMADERM, progressive multifocal leukoencephalopathy and the Federal Institute for Drugs and Medical Devices (BfArM)
Counterfeit medicines - a growing problem
|
|
|
CURRENT ADR NETWORK REPORT
|
|
Lichenoid reactions on beta-receptor blockers
|
|
|
SIDE EFFECTS
|
|
Minocycline (SKID u.a.): market withdrawal overdue
|
|